MGI(SH:688114) 仪器信息网·2026-01-26 03:55Core Viewpoint - The company, Shenzhen BGI Genomics Co., Ltd., forecasts a significant reduction in losses for the year 2025, with expected net losses decreasing by over 50% compared to the previous year [2][4]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders ranging from -273 million to -221 million yuan for 2025, representing a reduction in losses of 32.78 million to 37.98 million yuan, which corresponds to a year-on-year decrease in losses of 54.56% to 63.22% [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -397 million and -322 million yuan, with a reduction in losses of 25.57 million to 33.07 million yuan, indicating a year-on-year decrease in losses of 39.18% to 50.67% [2][4]. Group 2: Previous Year Performance - In the previous year, the total profit was -549.78 million yuan, with a net profit attributable to shareholders of 600.82 million yuan and a net profit excluding non-recurring gains and losses of -652.71 million yuan [7]. - The earnings per share for the previous year were -1.46 yuan per share [8]. Group 3: Reasons for Performance Changes - The company implemented a series of measures aimed at improving quality and efficiency, which included enhancing employee productivity, focusing on research and development, and managing marketing expenses throughout the cycle, leading to a reduction in costs compared to the same period last year [9]. - Fluctuations in the exchange rates of the US dollar and Euro resulted in increased foreign exchange gains from the company's foreign currency-denominated assets [9]. - The company reversed tax provisions related to uncertainties from previous years, resulting in a decrease in income tax expenses year-on-year [9]. - The company has made provisions for asset impairments in accordance with accounting standards and policies, based on the principle of prudence [9].